ATE481101T1 - Verfahren zur behandlung von angstzuständen - Google Patents
Verfahren zur behandlung von angstzuständenInfo
- Publication number
- ATE481101T1 ATE481101T1 AT04746014T AT04746014T ATE481101T1 AT E481101 T1 ATE481101 T1 AT E481101T1 AT 04746014 T AT04746014 T AT 04746014T AT 04746014 T AT04746014 T AT 04746014T AT E481101 T1 ATE481101 T1 AT E481101T1
- Authority
- AT
- Austria
- Prior art keywords
- disorder
- adenosine
- receptor antagonist
- treating anxiety
- anxiety
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 230000036506 anxiety Effects 0.000 title 1
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 abstract 2
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 abstract 2
- 208000008811 Agoraphobia Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 206010034912 Phobia Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 201000001716 specific phobia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50904603P | 2003-06-10 | 2003-06-10 | |
| US53279303P | 2003-12-24 | 2003-12-24 | |
| PCT/JP2004/008486 WO2004108137A1 (en) | 2003-06-10 | 2004-06-10 | A method of treating an anxiety disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE481101T1 true ATE481101T1 (de) | 2010-10-15 |
Family
ID=33514319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04746014T ATE481101T1 (de) | 2003-06-10 | 2004-06-10 | Verfahren zur behandlung von angstzuständen |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8202869B2 (enExample) |
| EP (1) | EP1631294B1 (enExample) |
| JP (1) | JP4778894B2 (enExample) |
| KR (1) | KR20060037252A (enExample) |
| CN (1) | CN1787821A (enExample) |
| AT (1) | ATE481101T1 (enExample) |
| AU (1) | AU2004244906A1 (enExample) |
| BR (1) | BRPI0411120A (enExample) |
| CA (1) | CA2528710C (enExample) |
| CO (1) | CO5640121A2 (enExample) |
| DE (1) | DE602004029160D1 (enExample) |
| EA (1) | EA200501924A1 (enExample) |
| MX (1) | MXPA05013148A (enExample) |
| NO (1) | NO20055907L (enExample) |
| WO (1) | WO2004108137A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150080013A (ko) * | 2002-01-28 | 2015-07-08 | 교와 핫꼬 기린 가부시키가이샤 | 운동성 질환에 걸린 환자의 치료용 조성물 |
| US10042980B2 (en) | 2005-11-17 | 2018-08-07 | Gearbox Llc | Providing assistance related to health |
| US20070124176A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
| US20070136092A1 (en) * | 2005-11-30 | 2007-06-14 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging |
| US10296720B2 (en) | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
| US7994190B2 (en) | 2006-11-01 | 2011-08-09 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US20090082341A1 (en) * | 2007-07-23 | 2009-03-26 | Synosia Therapeutics | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER |
| UA113383C2 (xx) | 2009-09-02 | 2017-01-25 | Терапевтичний агент для лікування тривожних розладів | |
| UA110097C2 (uk) | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
| US8609162B2 (en) | 2012-10-04 | 2013-12-17 | Invivo Beverages Llc | Integrated neuromodulation system for mood enhancement of a living human subject |
| CN105770563A (zh) * | 2016-04-22 | 2016-07-20 | 孙建 | 一种治疗焦虑症的中药制剂及其制备方法 |
| WO2019168847A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
| JOP20200342A1 (ar) | 2018-07-05 | 2020-12-30 | Incyte Corp | مشتقات بيرازين مدمجة كمثبطات a2a/a2b |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| WO2022167778A1 (en) | 2021-02-02 | 2022-08-11 | Haiku Therapeutics Ltd | Ebselen as adenosine receptor modulator |
| KR102594242B1 (ko) | 2023-01-10 | 2023-10-27 | 주식회사 웨이센 | 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치 |
| KR102567684B1 (ko) | 2023-01-10 | 2023-08-18 | 주식회사 웨이센 | 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2051772T3 (es) * | 1986-09-30 | 1994-07-01 | Ciba Geigy Ag | 2-sustituido-e-fusionado-(1,2,4)-triazol(1,5-c)pirimidinas, composiciones farmaceuticas y sus usos. |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| US5484920A (en) | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
| PT628311E (pt) | 1992-07-08 | 2002-09-30 | Kyowa Hakko Kogyo Kk | Derivado de xantina com actividade antidepressiva |
| ES2264210T3 (es) | 1997-09-05 | 2006-12-16 | Kyowa Hakko Kogyo Co., Ltd. | Derivados de xantina para el tratamiento de la isquemia cerebral. |
| BR9914040A (pt) | 1998-09-22 | 2002-01-15 | Kyowa Hakko Kogyo Kk | Derivados de [1,2,4]triazolo[1,5-c]pirimidina e seu uso, medicamento, antagonista, agente para prevenir ou tratar doenças, bem como processo para prevenção ou tratamento de distúrbios |
| WO2000069464A1 (en) * | 1999-05-12 | 2000-11-23 | Fujisawa Pharmaceutical Co., Ltd. | Novel use |
| JP4574112B2 (ja) * | 2000-05-26 | 2010-11-04 | シェーリング コーポレイション | アデノシンａ２ａレセプターアンタゴニスト |
| CA2459304A1 (en) * | 2001-09-13 | 2003-03-20 | Schering Corporation | Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
| JP4545437B2 (ja) * | 2001-10-15 | 2010-09-15 | シェーリング コーポレイション | アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン |
| WO2003043637A1 (en) * | 2001-11-20 | 2003-05-30 | Bristol-Myers Squibb Pharma Company | 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands |
| US20060128694A1 (en) * | 2002-12-19 | 2006-06-15 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
-
2004
- 2004-06-10 KR KR1020057021878A patent/KR20060037252A/ko not_active Withdrawn
- 2004-06-10 AU AU2004244906A patent/AU2004244906A1/en not_active Abandoned
- 2004-06-10 CN CNA2004800128457A patent/CN1787821A/zh active Pending
- 2004-06-10 DE DE602004029160T patent/DE602004029160D1/de not_active Expired - Lifetime
- 2004-06-10 EA EA200501924A patent/EA200501924A1/ru unknown
- 2004-06-10 CA CA2528710A patent/CA2528710C/en not_active Expired - Fee Related
- 2004-06-10 BR BRPI0411120-6A patent/BRPI0411120A/pt not_active IP Right Cessation
- 2004-06-10 US US10/553,250 patent/US8202869B2/en not_active Expired - Fee Related
- 2004-06-10 AT AT04746014T patent/ATE481101T1/de not_active IP Right Cessation
- 2004-06-10 MX MXPA05013148A patent/MXPA05013148A/es unknown
- 2004-06-10 EP EP04746014A patent/EP1631294B1/en not_active Expired - Lifetime
- 2004-06-10 JP JP2006516839A patent/JP4778894B2/ja not_active Expired - Fee Related
- 2004-06-10 WO PCT/JP2004/008486 patent/WO2004108137A1/en not_active Ceased
-
2005
- 2005-12-13 NO NO20055907A patent/NO20055907L/no not_active Application Discontinuation
-
2006
- 2006-01-10 CO CO06001545A patent/CO5640121A2/es not_active Application Discontinuation
-
2012
- 2012-04-16 US US13/447,798 patent/US8592420B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1787821A (zh) | 2006-06-14 |
| US20060281770A1 (en) | 2006-12-14 |
| AU2004244906A1 (en) | 2004-12-16 |
| MXPA05013148A (es) | 2006-03-17 |
| US8202869B2 (en) | 2012-06-19 |
| WO2004108137A1 (en) | 2004-12-16 |
| CO5640121A2 (es) | 2006-05-31 |
| NO20055907L (no) | 2005-12-13 |
| US8592420B2 (en) | 2013-11-26 |
| CA2528710C (en) | 2012-04-17 |
| EA200501924A1 (ru) | 2006-06-30 |
| BRPI0411120A (pt) | 2006-07-18 |
| DE602004029160D1 (enExample) | 2010-10-28 |
| JP4778894B2 (ja) | 2011-09-21 |
| KR20060037252A (ko) | 2006-05-03 |
| CA2528710A1 (en) | 2004-12-16 |
| EP1631294A1 (en) | 2006-03-08 |
| US20120232089A1 (en) | 2012-09-13 |
| EP1631294B1 (en) | 2010-09-15 |
| JP2006527264A (ja) | 2006-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE481101T1 (de) | Verfahren zur behandlung von angstzuständen | |
| CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
| ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
| ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| EP1427377A4 (en) | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING SKIN DISORDERS USING SPECIFIC BINDING AGENTS FOR A PROSTATE-SPECIFIC MEMBRANE ANTIGEN | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| DE60314500D1 (de) | Diaminopyrimidine und deren verwendung als angiogenesehemmer | |
| ATE464303T1 (de) | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen | |
| DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
| ATE542803T1 (de) | Verfahren zur herstellung von dihydrochinazolinen | |
| DE69939312D1 (de) | Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen | |
| ATE478661T1 (de) | Verfahren zur reduzierung der angiogenese | |
| DE602004012578D1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
| TW200507840A (en) | Method of treating multiple myeloma | |
| DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
| DE602006008583D1 (de) | Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung | |
| ATE446299T1 (de) | Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin | |
| DE60239450D1 (de) | Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten | |
| WO2007053796A3 (en) | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion | |
| ATE453386T1 (de) | Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten | |
| BRPI0408077A (pt) | composições e métodos para prevenção e tratamento de doenças relacionadas com endotoxina e condições | |
| DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
| ATE342372T1 (de) | Verfahren zur herstellung von d-pantothensäure und/oder deren salze als zusatz zu tierfuttermitteln | |
| EA200501052A1 (ru) | Способ лечения поведенческих расстройств |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |